Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.

G. Frasci,P. Comella,Ignazio Carreca,Giuseppe Decataldis,D Muci,Cosimo Brunetti,Anna Russo,Sergio Palmeri,R. DAniello,Renato Giordano,Massimiliano D’Aiuto,G. Comella

Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.

2005

G. Frasci
P. Comella
Ignazio Carreca
Giuseppe Decataldis
D Muci
Cosimo Brunetti
Anna Russo
Sergio Palmeri
R. DAniello
Renato Giordano
Massimiliano D’Aiuto
G. Comella

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor

Keywords:

Immunology
Pathology
Phases of clinical research
Granulocyte colony-stimulating factor
Cancer
Cisplatin
Paclitaxel
Lung cancer
Epirubicin
Medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations